Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Use of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRE

Award Number: R21AI151363
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 11/24/2020
PERIOD OF PERFORMANCE END DATE: 10/31/2024

Group Awards By:

View Award Description

Use of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRE - ABSTRACT Carbapenem-resistant Enterobacteriaceae (CRE) continue to be a global public health threat and priority for antimicrobial development efforts. Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp) is the predominant pathogen; however, prevalence rates have decreased in endemic regions resulting in a more diverse CRE landscape that includes both KPC and non-KPC producing pathogens. Ceftazidime-avibactam (CAZ-AVI), a novel β-lactam/β-lactamase inhibitor (BL/BLI) that has become the front- line treatment of CRE infections, resulting in superior efficacy and safety compared to prior salvage regimens. Despite these encouraging findings, CAZ-AVI resistance emerged in 10% of patients following courses of 7 – 19 days. We identified mutations in blaKPC-3 encoding variant KPC-3 enzymes responsible for resistance. Variant KPC enzymes displayed reverted susceptibility to carbapenems. Two newer BL/BLI agents, meropenem- vaborbactam (MER-VAB) and imipenem-relebactam (IMI-REL) feature a carbapenem backbone that may provide stability against blaKPC mutations; however, we have showed that their activity against CRE is compromised by porin gene mutations that decrease outer membrane permeability. It is unclear how frequently resistance will emerge to each of the new BL/BLI agents. Antibiotic combination therapy is a common strategy to treat CRE infections; however, ideal BL/BLI combination regimens are not defined, nor are dosing regimens that optimize activity and reduce the selection of resistant mutants. Our primary objectives in this project are to understand mechanisms by which CRE develop resistance to CAZ-AVI, MER-VAB, and IMI-REL, and to identify strategies that effectively suppress the emergence of resistance. To accomplish these objectives we will investigate new and previously defined resistance mechanisms and suppression of resistance by partnering BL/BLI agents with other recently-approved agents that offer complimentary mechanisms or dual BL agents with each BLI. In specific aim 1, we will determine the frequency (aim 1a) and mechanisms (aim 1b) by which resistance emerges against BL/BLI agents in a dynamic hollow-fiber infection model. BL/BLI exposures will be modeled using serum and epithelial lining fluid (ELF) pharmacokinetics that are achieved during bacteremia and pneumonia, respectively. In specific aim 2, we will define BL/BLI combination regimens that suppress the emergence of resistance in hollow-fiber (aim 2a) and murine pneumonia (aim 2b) models. To do so, we will screen novel combination regimens in time-kill analyses by partnering BL/BLI agents with eravacycline, fosfomycin, and plazomicin, or CAZ-AVI plus MER or IMI and CAZ plus MER-VAB or IMI-REL. The most active combinations will be validated against representative CRE clinical isolates with diverse mechanisms. The results of this study will generate timely, clinically-relevant data that provides new information on optimized treatment regimens in the face of a rapidly changing CRE landscape. Moreover, we will define novel mechanisms of resistance, and use these data to better define the therapeutic niche of each newly-approved, CRE-active agent.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Allergy and Infectious Diseases Research	000	2	5/12/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	4200 FIFTH AVENUE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Allergy and Infectious Diseases Research	000	2	1/10/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $196,667 )
2022	2022	UNIVERSITY OF PITTSBURGH, THE	4200 5TH AVE	PITTSBURGH	PA	15260	ALLEGHENY	USA	Allergy and Infectious Diseases Research	000	2	11/8/2021	NON-COMPETING CONTINUATION	$196,667
														Subtotal = $196,667

Issue Date FY: 2021 ( Subtotal = $234,750 )
2021	2021	UNIVERSITY OF PITTSBURGH THE	3520 FIFTH AVE	PITTSBURGH	PA	15213	ALLEGHENY	USA	Allergy and Infectious Diseases Research	000	1	11/23/2020	NEW	$234,750
														Subtotal = $234,750

Grand Total All Awards = $431,417

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Use of site-specific pharmacokinetics to optimize antibiotic combinations and prevent the emergence of resistance against CRE

Award Number: R21AI151363

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 11/24/2020

PERIOD OF PERFORMANCE END DATE: 10/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer